|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
Pharmacyclics
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
oncology drugs
COVID-19 treatments
HIV treatments
Hepatitis B treatments
|
|
gptkbp:employees
|
over 13,000
|
|
gptkbp:founded
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:headCoach
|
approximately 13,000
|
|
gptkbp:headquarters
|
gptkb:Foster_City,_California,_USA
gptkb:Foster_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences, Inc.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market
|
$80 billion (2021)
|
|
gptkbp:notableFeature
|
gptkb:Vemlidy
gptkb:Yescarta
gptkb:Atripla
gptkb:Sovaldi
gptkb:Truvada
Biktarvy
Remdesivir
Descovy
Cimzia
Veklury
Zydelig
|
|
gptkbp:partnerships
|
gptkb:Galapagos_NV
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
Gilead's_COVID-19_response
Gilead's_HIV_initiative
Gilead's_hepatitis_initiative
|
|
gptkbp:products
|
Antiviral drugs
HIV medications
Hepatitis C treatments
|
|
gptkbp:researchFocus
|
oncology
inflammation
infectious diseases
|
|
gptkbp:revenue
|
$24.69 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences_UK_Ltd.
gptkb:Gilead_Sciences_Singapore_Pte._Ltd.
gptkb:Gilead_Sciences_Ireland_UC
gptkb:Gilead_Sciences_Canada,_Inc.
gptkb:Gilead_Sciences_Australia_Pty_Ltd.
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.gilead.com
|